Literature DB >> 19090738

Management options for minimal hepatic encephalopathy.

Jasmohan S Bajaj1.   

Abstract

Minimal hepatic encephalopathy (MHE) is a neurocognitive dysfunction that is present in the majority of patients with cirrhosis. MHE has a characteristic cognitive profile that cannot be diagnosed clinically. This cognitive dysfunction is independent of sleep dysfunction or problems with overall intelligence. MHE has a significant impact on quality of life, the ability to function in daily life and progression to overt hepatic encephalopathy. Driving ability can be impaired in MHE and this may be a significant factor behind motor vehicle accidents. A crucial aspect of the clinical care of MHE patients is their driving history, which is often ignored during routine care and can add a vital dimension to the overall disease assessment. Driving history should be an integral part of the care of patients with MHE. The preserved communication skills and lack of specific signs and insight make MHE difficult to diagnose. The predominant strategies for MHE diagnosis are psychometric or neurophysiological testing. These are usually limited by financial, normative or time constraints. Studies into inhibitory control, cognitive drug research and critical flicker frequency tests are encouraging. These tests do not require a psychologist for administration and interpretation. Lactulose and probiotics have been studied for their potential use as therapies for MHE, but these are not standard-of-care practices at this time. Therapy can improve the quality of life in MHE patients but the natural history, specific diagnostic strategies and treatment options are still being investigated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19090738     DOI: 10.1586/17474124.2.6.785

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  15 in total

Review 1.  Management of covert hepatic encephalopathy.

Authors:  Abhijeet Waghray; Nisheet Waghray; Kevin Mullen
Journal:  J Clin Exp Hepatol       Date:  2014-04-01

2.  Hybrid bioartificial liver support in cynomolgus monkeys with D-galactosamine-induced acute liver failure.

Authors:  Zhi Zhang; Yi-Chao Zhao; Yuan Cheng; Guo-Deng Jian; Ming-Xin Pan; Yi Gao
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

3.  Treatment options for covert hepatic encephalopathy.

Authors:  Nisheet Waghray; Abhijeet Waghray; Kevin Mullen
Journal:  Curr Treat Options Gastroenterol       Date:  2014-06

Review 4.  Useful tests for hepatic encephalopathy in clinical practice.

Authors:  Eiman Nabi; Jasmohan S Bajaj
Journal:  Curr Gastroenterol Rep       Date:  2014-01

Review 5.  Mechanisms, diagnosis and management of hepatic encephalopathy.

Authors:  Ravi Prakash; Kevin D Mullen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-10       Impact factor: 46.802

Review 6.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

Review 7.  Encephalopathy and liver transplantation.

Authors:  Laia Chavarria; Juan Cordoba
Journal:  Metab Brain Dis       Date:  2012-11-16       Impact factor: 3.584

Review 8.  Hyperammonemia in Hepatic Encephalopathy.

Authors:  A R Jayakumar; Michael D Norenberg
Journal:  J Clin Exp Hepatol       Date:  2018-06-20

Review 9.  The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies.

Authors:  Lorenzo Ridola; Vincenzo Cardinale; Oliviero Riggio
Journal:  Ann Gastroenterol       Date:  2018-02-01

10.  JianPi HuaZhuo XingNao formula (Chinese herbal medicine) for the treatment of minimal hepatic encephalopathy: a protocol for a randomized, placebo-controlled pilot trial.

Authors:  XiaoKe Li; DaNan Gan; Ying Li; Peng Zhang; ZhiGuo Li; HongBo Du; LuDan Zhang; Yuan Cheng; YaQiang Zhang; YiJun Liang; YongAn Ye
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.